JSPR — Jasper Therapeutics Balance Sheet
0.000.00%
Last trade - 00:00- $81.27m
- $9.63m
Annual balance sheet for Jasper Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Cash and Short Term Investments | 19.8 | 84.7 | 38.3 | 86.9 | 71.6 |
| Net Total Receivables | 0.6 | 0.698 | 0.913 | 0.25 | 0 |
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 20.7 | 87.8 | 41.7 | 88.9 | 75.8 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 2.03 | 4.83 | 5.45 | 4.19 | 2.85 |
| Other Long Term Assets | |||||
| Total Assets | 23.4 | 93.7 | 48.4 | 94.9 | 79.9 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 4.01 | 8.02 | 7.07 | 12.4 | 15.2 |
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 14.6 | 24.1 | 12.4 | 16.5 | 18.2 |
| Redeemable Preferred Stock | |||||
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Total Equity | 8.71 | 69.5 | 36 | 78.4 | 61.7 |
| Total Liabilities & Shareholders' Equity | 23.4 | 93.7 | 48.4 | 94.9 | 79.9 |
| Total Common Shares Outstanding |